- Entry
- $7.40
- Final
- $10.05 +35.8%
- Target
- —
- Score
- +1.00
Merck announced this week that it is creating a separate cancer business, as it braces for the loss of patent protection on Keytruda, the cancer treatment that accounts for nearly half of the company’s revenue. Merck is taking steps to evolve the structure of its Human Health organization, creating two separate divisions, one for cancer and one for the rest. Why now? They are facing two threats to the revenue they get from Keytruda, the #1 selling drug in the …
— ORIGINAL POST ·
Merck faces double threat to lose up to half of its revenue, could a small study with DRTS save it?
· r/stocks
· Feb 25, 2026